期刊文献+

产质粒介导AmpC酶大肠埃希菌耐药分析及相关机制 被引量:2

Resistance and associated resistance mechanism of Escherichia coli producing plasmid-mediated AmpC β-lactamases
原文传递
导出
摘要 目的了解安徽省35所医院自临床分离的402株大肠埃希菌产质粒介导AmpC酶及对常用抗菌药物的耐药情况,揭示其相关耐药机制,以指导临床合理用药。方法以三维试验筛选产AmpC酶株;多重PCR检测产质粒介导AmpC酶菌株,对产质粒介导AmpC酶菌株用PCR方法检测超广谱β-内酰胺酶(ESBLs)基因、Ⅰ类整合子基因盒插入序列和主动外排系统acrAB-tolC基因。结果检出产质粒介导AmpC酶菌株28株(7.0%),其中两株经测序比对证实为新的质粒ampC基因型。产酶菌株对常用抗菌药物,除亚胺培南、美罗培南都敏感外,对其他大多数抗菌药物耐药率均高于非产酶株。28株产酶菌株中有23株表现为多重耐药,20株检测出各型ESBLs基因,21株扩增出Ⅰ类整合子基因盒插入序列,20株主动外排系统acrAB-tolC基因阳性。结论产质粒介导AmpC酶大肠埃希菌对临床常用抗菌药物的耐药率均较高,多重耐药现象普遍,同时存在多种耐药机制,其中以产生灭活酶和Ⅰ类整合子介导的耐药机制为主。对产酶菌株临床经验用药可选用碳青霉烯类、阿米卡星、四代头孢菌素类抗菌药物。 Objective To investigate the production and resistance of plasmid-mediated AmpC β-lactamase-producing Escherichia coli (E. coli) and analyze their associated resistance mechanism and guide rational use of antibiotics. Methods Three-dimensional extract test was adopted to detect AmpC β-lactamases. The plasmid-mediated AmpC β-lactamases were detected by multiplex PCR. Extended-spectrum β-lactamases (ESBLs) gene, inserted gene cassettes of class 1 integrons and active efflux system acrAB-tolC gene were amplified by PCR. Results Among the 402 isolates collected, 28 (7.0%) produced plasmid-media- ted AmpC β-lactamases. DNA sequence analysis confirmed that 2 were novel ampC genes. The resistant rates of AmpC β-lactamase-producing strains against most kinds of antibiotics were higher than the unproducing strains. They were all sensitive to imipenem and meropenem. Among the 28 strains, 23 were multipledrug resistance, 20 were determined as ESBLs gene positive, 21 as class 1 integrons sequence, and 20 as aerAB-tolC gene. Conclusions The resistance rates of AmpC β-lactamaseproducing E. coli against most kinds of antibiotics reach a high level. The AmpC producers are multiple-drug resistance and there may be several resistance mechanisms, in which class 1 integrons and production of AmpC and ESBLs were the main ones. Carbopenems, amikacin and fourth cephalosporins should be chosen in clinical empirical medication.
出处 《中华实验和临床感染病杂志(电子版)》 CAS 2007年第3期144-148,共5页 Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金 国家自然科学基金项目(30571654) 安徽省自然科学基金项目(070413110)
关键词 AMPC酶 大肠埃希菌 耐药 AmpC β-lactamases Escherichia coil Resistance
  • 相关文献

参考文献4

二级参考文献36

  • 1张永标,张扣兴,唐英春,陆坚,宋玮,朱家馨,谈淑卿.产质粒介导AmpC酶和ESBLs细菌的耐药性及β-内酰胺酶基因型研究[J].中华微生物学和免疫学杂志,2004,24(7):577-582. 被引量:80
  • 2王清涛,刘颖梅,王辉,孙宏莉,陈民钧,杜小玲.产超广谱β内酰胺酶菌株中质粒头孢菌素酶的研究[J].中华内科杂志,2004,43(7):487-490. 被引量:14
  • 3李可,张茂棠,徐亚军,兰全学,刘衡川.健康人群大肠埃希菌Ⅰ类整合子与多重耐药的相关性分析[J].现代预防医学,2005,32(2):118-120. 被引量:11
  • 4顾兵,童明庆.整合子与细菌耐药[J].临床检验杂志,2005,23(3):226-229. 被引量:46
  • 5MaloySR StewartVJ TaylorRK(徐建国 译).医用细菌遗传学实验指南[M].北京:科学出版社,1998.307-308. 被引量:2
  • 6Winokur P L, Vonstein D L, Hoffman L J, et al. Evidence for transfer of CMY-2 AmpC beta-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans [J]. Antimicrob Agents Chemother, 2001,45 (10) :2716. 被引量:1
  • 7Odeh R, Kelkar S, Hujer A M, et al. Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli [J]. Clin Infect Dis, 2002, 35(2):140. 被引量:1
  • 8Siu L K, Lu P L, Chen J Y, et al. High-level expression of AmpC beta-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extendedspectrum-cephalosporin treatment [J]. Antimicrob Agents Chemother,2003,47 (7): 2138. 被引量:1
  • 9Corvec S, Caroff N, Espaze E, et al. 11 Mutation in the ampC promoter increasing resistance to beta-lactams in a clinical Escherichia coli strain [J]. Antimicrob Agents Chemother , 2002,46 (10): 3265. 被引量:1
  • 10Petrosino J F, Pendleton A R, Weiner J H, et al. Chromosomal system for studying AmpC-mediated beta-lactam resistance mutation in Escherichia coli [J]. Antimicrob Agents Chemother, 2002,46 (5): 1535. 被引量:1

共引文献60

同被引文献13

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部